Details of the Drug Pharmacogenomic Perturbation Atlas

YM-201636 Drug Info

371942-69-7; YM201636; YM 201636; 6-Amino-N-[3-[4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl]phenyl]-3-pyridinecarboxamide; 3-pyridinecarboxamide, 6-amino-N-[3-[4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl]phenyl]-; 6-amino-n-(3-(4-(4-morpholinyl)pyrido(3',2'-4,5)furo(3,2-d)pyrimidin-2-yl)phenyl)-3-pyridinecarboxamide; 6-amino-N-[3-[4-(4-morpholinyl)-2-pyrido[2,3]furo[2,4-b]pyrimidinyl]phenyl]-3-pyridinecarboxamide; PubChem22459; cc-386; MLS006010997; SCHEMBL258416; CHEMBL2178735; CHEBI:91382; AOB1919; DTXSID90433303; EX-A037; QCR-257; BCPP000006; HMS3229J15; HMS3295C07; HMS3654F03; AMY23718; BCP01972; ABP000099; MFCD16038303; s1219; ZINC34048998; AKOS027250783; CCG-264866; CS-0592; NCGC00346683-01; NCGC00346683-09; 6-amino-N-[3-(4-morpholin-4-ylpyrido[2,3]furo[2,4-b]pyrimidin-2-yl)phenyl]pyridine-3-carboxamide; AK175782; AS-16693; HY-13228; SMR004702795; AB0035851; FT-0756177; SW218129-2; Y0272; A19418; W-5608; 942Y697; J-518249; BRD-K48488978-001-01-2; Q27163245; YM-201636,CAS:371942-69-7; 6-Amino-N-[3-(6-morpholin-4-yl-8-oxa-3,5,10-triazatricyclo[7.4.0.02,7]trideca-1(9),2(7),3,5,10,12-hexaen-4-yl)phenyl]pyridine-3-carboxamide; 6-Amino-N-{3-[4-(morpholin-4-yl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl]phenyl}pyridine-3-carboxamide

Cross-matching ID

PubChem CID

9956222

ChEBI ID

CHEMBL2178735

CAS Number

CAS 371942-69-7

TTD Drug ID

DPN2R7

General Information of Drug (ID: DMU86XT)

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Steroid biosynthesis	2.41	0.00e+0	19/20 (95%)	MSMO1;DHCR24;LSS;...
Terpenoid backbone biosynthesis	2.19	4.57e-3	18/22 (81.82%)	HMGCS1;ACAT2;IDI1;...
Lysosome	2.15	3.04e-3	115/128 (89.84%)	ASAH1;NPC2;CTSK;...
Oxidative phosphorylation	1.92	4.57e-3	93/133 (69.92%)	ATP6V0E1;ATP6V1G1;ATP5PD;...
Biosynthesis of unsaturated fatty acids	1.87	1.28e-2	21/27 (77.78%)	SCD;ELOVL6;FADS2;...
Primary bile acid biosynthesis	1.84	1.22e-2	15/17 (88.24%)	CH25H;SCP2;CYP7A1;...
Pentose phosphate pathway	1.79	1.83e-2	25/30 (83.33%)	ALDOC;FBP1;TALDO1;...
Sulfur metabolism	1.76	2.17e-2	9/10 (90%)	PAPSS2;SELENBP1;SQOR
Synthesis and degradation of ketone bodies	1.74	2.94e-2	9/10 (90%)	HMGCS1;ACAT2;BDH1
Collecting duct acid secretion	1.69	4.93e-2	22/27 (81.48%)	ATP6V0E1;ATP6V1G1;ATP6V0D1;...
Complement and coagulation cascades	-1.83	4.32e-2	76/85 (89.41%)	FGG;ITGB2;F3;...
Amoebiasis	-1.91	4.32e-2	99/102 (97.06%)	PRKACA;GNA15;GNAL;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Breast carcinoma

Breast epithelium

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF-10A	CVCL_0598	Homo sapiens	0.04uM - 10uM	3H, 6H, 24H

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.04uM - 10uM	24H

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.04uM - 10uM	24H

Liver

Hepatoblastoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Hep G2	CVCL_0027	Homo sapiens	0.04uM - 10uM	24H

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.04uM - 10uM	24H

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	0.04uM - 10uM	24H

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	0.04uM - 10uM	24H

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.04uM - 10uM	24H